歐洲監管機構稱亞馬遜收購或損競爭 iRobot(IRBT.US)股價挫近20%
歐盟委員會表示已通知亞馬遜(AMZN.US)對其收購吸塵機械人製造商iRobot(IRBT.US)的交易可能會損害競爭後,iRobot周一股價下跌近20%,亞馬遜升逾1%。
歐盟委員會周一在聲明中表示,亞馬遜有能力亦有動力,可能透過採取多種策略以取消iRobot的競爭對手,包括阻止競爭對手在亞馬遜的網上市場銷售,亦可以降低消費者對競爭對手的訪問能力。委員會必須在2月14日之前就合併做出最終決定。
上周傳出歐洲或批准亞馬遜對iRobot的交易,iRobot股價周五交易中收市大升39%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.